Skip to main content
Erschienen in: Endocrine 3/2021

06.07.2021 | Original Article

Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience

verfasst von: Camilla Bardasi, Andrea Spallanzani, Stefania Benatti, Francesca Spada, Alice Laffi, Lorenzo Antonuzzo, Daniele Lavacchi, Riccardo Marconcini, Marco Ferrari, Margherita Rimini, Francesco Caputo, Chiara Santini, Krisida Cerma, Andrea Casadei-Gardini, Kalliopi Andrikou, Massimiliano Salati, Federica Bertolini, Annalisa Fontana, Massimo Dominici, Gabriele Luppi, Fabio Gelsomino

Erschienen in: Endocrine | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Evidence of the effectiveness of chemotherapy is scarce. Platinum plus Etoposide regimens are currently the standard treatment in first-line, while little data are available on second-line treatments. The aim of this study is to evaluate the efficacy and safety of irinotecan (IRI)-based chemotherapy in a series of extrapulmonary NECs.

Methods

Patients with NEC diagnosis treated at University Hospitals of Modena, Florence, Pisa, and European Institute of Oncology of Milan with an IRI-based regimen (FOLFIRI or XELIRI) after progression to a first-line platinum-based therapy were enrolled. Objective responses were assessed according to RECIST criteria. Progression-free survival (PFS) and overall survival (OS) were calculated.

Results

Thirty-four patients, 16 males, and 18 females, median age of 59 years (range 32–77), with metastatic NEC were included. Twenty-seven patients had Ki-67 ≥ 55% and four patients Ki-67 of <55% (for three patients data were not available). The median number of treatment cycles of the IRI-based regimen was 7.5 (range 1–16). Six partial responses (17.6%) and 9 stable diseases (26.5%) were observed, with a disease control rate of 44.1%. Median PFS and OS were 4.4 and 5.9 months, respectively. Neutropenia, anemia, and nausea were the only G3–G4 toxicities reported.

Conclusions

Despite the relatively small sample size, IRI-based therapy demonstrated to be a valid option for patients with pretreated extrapulmonary NEC.
Literatur
1.
Zurück zum Zitat R. Garcia-Carbonero et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 21, 1794–1803 (2010)CrossRef R. Garcia-Carbonero et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 21, 1794–1803 (2010)CrossRef
2.
Zurück zum Zitat G. Rindi et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J. Natl Cancer Inst. 104, 764–777 (2012)CrossRef G. Rindi et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J. Natl Cancer Inst. 104, 764–777 (2012)CrossRef
3.
Zurück zum Zitat J. Strosberg et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum. Pathol. 40, 1262–1268 (2009)CrossRef J. Strosberg et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum. Pathol. 40, 1262–1268 (2009)CrossRef
4.
Zurück zum Zitat H. Sørbye et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 120, 2814–2823 (2014)CrossRef H. Sørbye et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 120, 2814–2823 (2014)CrossRef
5.
Zurück zum Zitat C.G. Moertel et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68, 227–232 (1991)CrossRef C.G. Moertel et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68, 227–232 (1991)CrossRef
6.
Zurück zum Zitat O. Hentic et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr. Relat. Cancer 19, 751–757 (2012)CrossRef O. Hentic et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr. Relat. Cancer 19, 751–757 (2012)CrossRef
7.
Zurück zum Zitat T. Yamaguchi et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105, 1176–1181 (2014)CrossRef T. Yamaguchi et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105, 1176–1181 (2014)CrossRef
8.
Zurück zum Zitat S. Welin et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117, 4617–4622 (2011)CrossRef S. Welin et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117, 4617–4622 (2011)CrossRef
9.
Zurück zum Zitat I.H. Olsen, et al. Temozolomide as second or third-line treatment of patients with neuroendocrine carcinomas. Sci. World J. 2012, 170496 (2012)CrossRef I.H. Olsen, et al. Temozolomide as second or third-line treatment of patients with neuroendocrine carcinomas. Sci. World J. 2012, 170496 (2012)CrossRef
10.
Zurück zum Zitat J. Hadoux et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr. Relat. Cancer 22, 289–298 (2015)CrossRef J. Hadoux et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr. Relat. Cancer 22, 289–298 (2015)CrossRef
12.
Zurück zum Zitat S. Munker et al. EpiCO (epirubicin, cyclophosphamide, and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. Z. Gastroenterol. 58(2), 133–136 (2020)CrossRef S. Munker et al. EpiCO (epirubicin, cyclophosphamide, and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. Z. Gastroenterol. 58(2), 133–136 (2020)CrossRef
13.
Zurück zum Zitat H. Sørbye et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24, 152–160 (2013)CrossRef H. Sørbye et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24, 152–160 (2013)CrossRef
Metadaten
Titel
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience
verfasst von
Camilla Bardasi
Andrea Spallanzani
Stefania Benatti
Francesca Spada
Alice Laffi
Lorenzo Antonuzzo
Daniele Lavacchi
Riccardo Marconcini
Marco Ferrari
Margherita Rimini
Francesco Caputo
Chiara Santini
Krisida Cerma
Andrea Casadei-Gardini
Kalliopi Andrikou
Massimiliano Salati
Federica Bertolini
Annalisa Fontana
Massimo Dominici
Gabriele Luppi
Fabio Gelsomino
Publikationsdatum
06.07.2021
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02813-y

Weitere Artikel der Ausgabe 3/2021

Endocrine 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.